Table 2.

Neutralization of SARS-CoV-2 by the nine EUA FDA and/or EMA antibodies. SARS-CoV-2 variant D614G was reported as early in the COVID-19 pandemic as January 2020. Omicron variant was reported almost two years later (November 2021).

(INN)	D614G	(Omicron)
Casirivimab plus Imdevimab	++++	−
Bamlanivimab plus Etesivimab	++++	−
Cilgavimab plus Tixagevimab	++++	Cilgavimab (++)
		Tixagevimab (+)
Regdanvimab	++++	−
Sotrovimab	++	++
Bebtelovimab	++++	++++

Data were taken and modified from Van Blargan et al. [33] and Westendorf et al. [34].